Research and development of next-generation antibodies, nucleic acid therapeutics and novel technologies
First written in FY2016. 14 of 24 entries say "Restated". Latest entry: FY2024-Q3.
4 other companies' latest entry also says "Restated".
- FY2024-Q3RestatedAnnual report
「In addition, regarding the anti-RAMP2 antibody, for which a patent grant was received in December 2022 and which inhibits neovascularization through a new mechanism, the company is currently actively pursuing out-licensing to development partner companies.」
The company has reconfirmed its policy of pursuing out-licensing to development partner companies after the patent grant for the anti-RAMP2 antibody. - FY2024-Q1AdvancedAnnual report
「In addition, regarding the anti-RAMP2 antibody, for which a patent grant was received in December 2022 and which inhibits neovascularization through a new mechanism, the company is currently actively pursuing out-licensing to development partner companies.」
The company expressly states that, in addition to continuing research and development after the patent grant for the anti-RAMP2 antibody, it is pursuing out-licensing to development partner companies. - FY2023-Q3AdvancedAnnual report
「In May 2022, the company entered into a joint research agreement with Chiome Bioscience Inc. concerning the development of antibody drugs and began development activities for its antibody drug candidates in oncology, with the aim of conducting joint research by combining the technologies and expertise of both companies. It is also steadily advancing development activities for its pipelines alongside its intellectual property strategy, including receiving a patent grant for the anti-RAMP2 antibody, which inhibits neovascularization through a new mechanism.」
The company continued joint research with Chiome Bioscience Inc. and achieved the concrete intellectual property milestone of receiving a patent grant for the anti-RAMP2 antibody. - FY2023-Q2RestatedAnnual report
「In May 2022, the company entered into a joint research agreement with Chiome Bioscience Inc. concerning the development of antibody drugs and began development activities for its antibody drug candidates in oncology, with the aim of conducting joint research by combining the technologies and expertise of both companies. It is also steadily advancing development activities for its other development pipelines.」
The company continues research and development of next-generation antibody drugs and other pipelines, including joint research with Chiome Bioscience Inc. - FY2023-Q1AdvancedAnnual report
「In May 2022, we entered into a joint research agreement with Chiome Bioscience Inc. concerning the development of antibody drugs and began development activities aimed at jointly researching development candidates for antibody drugs in the oncology field held by our company, combining the technologies and expertise of both companies.」
Research and development of next-generation antibody drugs progressed to the execution of a joint research agreement with Chiome Bioscience Inc. and the start of development activities for antibody drug candidates in oncology. - FY2022-Q3RestatedAnnual report
「As announced in the aforementioned five-year medium-term management plan, the company is advancing research and development and partnering activities for early-stage novel drug pipelines targeting curative treatments for malignant lymphoma, vasculitis and pulmonary hypertension.」
The company continues research and development and partnering activities for early-stage novel drug pipelines targeting malignant lymphoma, vasculitis and pulmonary hypertension. - FY2022-Q2RestatedAnnual report
「As announced in the aforementioned five-year medium-term management plan, the company is advancing research and development and partnering activities for early-stage novel drug pipelines targeting curative treatments for malignant lymphoma, vasculitis and pulmonary hypertension.」
The company continues research and development and partnering activities for early-stage novel drug pipelines targeting malignant lymphoma, vasculitis and pulmonary hypertension. - FY2022-Q1AdvancedAnnual report
「As announced in the aforementioned five-year medium-term management plan, the company is advancing research and development and partnering activities for early-stage novel drug pipelines targeting curative treatments for malignant lymphoma, vasculitis and pulmonary hypertension.」
The company specifically states that it is advancing research and development and partnering activities for early-stage novel drug pipelines targeting malignant lymphoma, vasculitis and pulmonary hypertension. - FY2021-Q3RestatedAnnual report
「As a result of advancing research and development of next-generation antibody drugs and other programs, the company entered into a joint research agreement with Sapporo Medical University in January 2020 to develop an anticancer drug using an antibody capable of entering cancer cells, and a separate joint research agreement with MabGenesis㈱ to obtain a novel antibody with cancer cell-killing effects. It continues research and development activities across these programs and its other development pipelines.」
The company continues research and development of next-generation antibody drugs based on joint research agreements with Sapporo Medical University and MabGenesis, along with activities involving its other pipelines. - FY2021-Q1RestatedAnnual report
「As a result of advancing research and development of next-generation antibody drugs and other programs, the company entered into a joint research agreement with Sapporo Medical University in January 2020 to develop an anticancer drug using an antibody capable of entering cancer cells, and a separate joint research agreement with MabGenesis㈱ to obtain a novel antibody with cancer cell-killing effects. It continues research and development activities across these programs and its other development pipelines.」
The company continues research and development of next-generation antibody drugs under joint research agreements with Sapporo Medical University and MabGenesis. - FY2020RestatedAnnual report
「In January 2020, we entered into a joint research agreement with Sapporo Medical University to develop an anticancer drug using antibodies capable of entering cancer cells, and a separate joint research agreement with MabGenesis㈱ to obtain novel antibodies with cancer-cell-killing effects.」
The company has reconfirmed its efforts in next-generation antibody drug research and development through joint research agreements with Sapporo Medical University and MabGenesis. - FY2020-Q3AdvancedAnnual report
「In January 2020, the company entered into a joint research agreement with Sapporo Medical University to develop an anticancer drug using an antibody capable of entering cancer cells, and a separate joint research agreement with MabGenesis㈱ to obtain a novel antibody with cancer cell-killing effects.」
Research and development of next-generation antibody drugs progressed to the execution of 2 joint research agreements aimed at developing anticancer drugs and obtaining novel antibodies. - FY2020-Q1RestatedAnnual report
「Research and development of next-generation antibody drugs led to the successful creation of an anti-RAMP2 antibody that inhibits neovascularization through a new mechanism. As a drug candidate expected to treat eye diseases and exert antitumor effects in oncology, the company filed a patent application for the antibody in September 2017 and an international patent application in September 2018. Going forward, it aims to advance research and development of the candidate antibody while securing intellectual property rights and to out-license it to a pharmaceutical company.」
The company continues to report the creation of the anti-RAMP2 antibody, domestic and international patent applications, and its goal of out-licensing the program to a pharmaceutical company. - FY2019Cited as achievedAnnual report
「As a drug candidate expected to treat eye diseases and exert antitumor effects in oncology, the company filed a patent application for this development program in September 2017 and an international patent application in September 2018. Going forward, it aims to advance research and development while securing intellectual property rights and to out-license the program to a pharmaceutical company.」
The company has reiterated the filing of domestic and international patent applications for the anti-RAMP2 antibody and its goal of out-licensing the program in the future. - FY2019-Q2AdvancedAnnual report
「The company successfully created an anti-RAMP2 antibody that inhibits neovascularization through a new mechanism and filed a patent application for the antibody in September 2017 as a drug candidate expected to treat eye diseases and exert antitumor effects in oncology. In September 2018, it filed an international patent application.」
The anti-RAMP2 antibody progressed from a domestic patent application to the filing of an international patent application in September 2018. - FY2019-Q1RestatedAnnual report
「Meanwhile, in the biologics business, research and development of next-generation antibody drugs led to the successful creation of a novel antibody that inhibits neovascularization through a new mechanism. As a drug candidate expected to treat eye diseases and exert antitumor effects in oncology, a patent application for the antibody was filed in September 2017.」
The company continues to create novel antibodies and file patent applications, while exploring novel technologies including nucleic acid drugs and exosomes. - FY2018RestatedAnnual report
「The company is conducting research on multiple antibody drug and nucleic acid drug candidates under in-house development. In September 2017, it successfully created the candidate antibody GND-004, a novel antibody drug that inhibits neovascularization through a new mechanism, and filed a patent application.」
The company has reiterated its ongoing activities involving research on next-generation antibodies and nucleic acid drugs, creation of GND-004 and the filing of a patent application. - FY2018-Q3RestatedAnnual report
「Meanwhile, in the biologics business, research and development of next-generation antibody drugs led to the successful creation of a novel antibody that inhibits neovascularization through a new mechanism. As a drug candidate expected to treat eye diseases and exert antitumor effects in oncology, a patent application for the antibody was filed in September 2017.」
The company has reiterated its research and development activities for next-generation antibodies and other programs, including the successful creation of a novel antibody and the filing of a patent application. - FY2018-Q2AdvancedAnnual report
「Meanwhile, in the biologics business, research and development of next-generation antibody drugs led to the successful creation of a novel antibody that inhibits neovascularization through a new mechanism. As a drug candidate expected to treat eye diseases and exert antitumor effects in oncology, a patent application for the antibody was filed in September 2017.」
Research and development of next-generation antibodies achieved concrete progress through the successful creation of a novel antibody and the filing of a patent application in September 2017. - FY2017AdvancedAnnual report
「The company is conducting research activities on multiple antibody drug and nucleic acid drug candidates under in-house development. One antibody drug is expected to generate intellectual property, and preparations are under way for a patent application. The company mainly advanced GND-004 as an anticancer antibody drug and GND-007 as a nucleic acid drug. For GND-007 in particular, drug delivery system (DDS) technology is a key development issue, so the company continues to investigate a wide range of technologies.」
In addition to continuing research on next-generation antibodies and nucleic acid drugs, the company reports that one antibody drug is expected to generate intellectual property, preparations are under way for a patent application, and DDS technologies for GND-007 are being investigated. - FY2017-Q3RestatedAnnual report
「Meanwhile, in the biologics business, the company advanced research and development of next-generation antibody drugs and explored opportunities for drug discovery using nucleic acids through its nucleic acid joint business with GeneDesign, Inc., which joined the Ajinomoto Group in December 2016. It also focused on acquiring novel technologies such as exosomes for which it jointly filed a patent application with the National Cancer Center.」
The company continues to explore novel drug discovery technologies, including next-generation antibodies, nucleic acids and exosomes. - FY2017-Q2RestatedAnnual report
「Meanwhile, in the biologics business, the company is advancing research and development of next-generation antibody drugs, exploring opportunities to develop nucleic acids as pharmaceuticals through its nucleic acid joint business with GeneDesign, Inc., and focusing on acquiring novel technologies such as exosomes for which it jointly filed a patent application with the National Cancer Center.」
While prioritizing biosimilars, the company also continues to explore novel drug discovery technologies, including next-generation antibodies, nucleic acids and exosomes. - FY2017-Q1RestatedAnnual report
「Meanwhile, in the biologics business, the company is advancing research and development of next-generation antibody drugs, exploring opportunities to develop nucleic acids as pharmaceuticals through its nucleic acid joint business with GeneDesign, Inc., and focusing on acquiring novel technologies such as exosomes for which it jointly filed a patent application with the National Cancer Center.」
While prioritizing biosimilars, the company continues to explore novel drug discovery technologies, including next-generation antibodies, nucleic acids and exosomes. - FY2016First statedAnnual report
「In the biologics business, the company is advancing research and development of next-generation antibody drugs, exploring opportunities to develop nucleic acids as pharmaceuticals through its nucleic acid joint business with GeneDesign, Inc., and focusing on acquiring novel technologies such as exosomes for which it jointly filed a patent application with the National Cancer Center.」
The company is exploring novel drug discovery technologies, including the antibody drug GND-004, nucleic acid drug GND-007 and exosomes.